Beacon Equity Research announces the release of Stock Alerts covering leading movers in the news: Immunomedics Inc. (Nasdaq: IMMU), Merck & Co. Inc. (NYSE: MRK), Marvell Technology Group Ltd. (Nasdaq: MRVL), Deere & Co.(NYSE: DE), Melco Crown Entertainment Ltd. (Nasdaq: MPEL) and Campbell Soup Co. (NYSE: CPB).
The stock alert features the most recent headlines, share price and technical analysis for each covered company. The full alert, as well as other articles, market research and more can be found at BeaconEquity.com
In the Stock Alert, the author highlights Immunomedics’ reporting on its first clinical study of milatuzumab:
“Immunomedics Inc. (Nasdaq: IMMU) shares rose 2.41% to $2.56 midday today. The New Jersey-based biopharmaceutical company, presenting at the 2009 Annual Meeting of American Society of Clinical Oncology, reported results from studies of milatuzumab, the company's proprietary humanized anti-CD74 antibody. Immunomedics is focused on developing monoclonal antibodies to treat cancer and other serious diseases. … According to the news release, the goal of this first clinical study of milatuzumab is to evaluate its safety, tolerability and feasibility in patients with multiple myeloma. Other objectives include preliminary information on efficacy, pharmacokinetics, immunogenicity, and acceptable doses for subsequent studies. … The company said milatuzumab produced disease stabilization in some patients with multiple myeloma and is well tolerated at doses up to 16.0 mg/kg. Milatuzumab has reportedly shown efficacy in preclinical B-lymphoma models, particularly multiple myeloma. In addition, milatuzumab is rapidly internalized when bound to its receptor, thus making CD-74 a promising target for conjugated drug delivery.”
The Stock Alert author also featured Merck and AstraZeneca agreeing to work together to test two early-stage cancer drugs:
“Merck & Co. Inc. (NYSE: MRK) shares slipped .40% midday today, trading at $27.45. Merck is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of products to improve human and animal health. … Merck and AstraZeneca recently announced they will test two early-stage cancer drugs together after preclinical evidence suggested that combining the two targeted therapies could make them more effective. … Both companies agreed on working together to research a novel combination anticancer regimen composed of two investigational compounds, MK-2206 from Merck and AZD6244 from AstraZeneca. Preclinical evidence indicates that combined administration of these compounds could enhance their anticancer properties. Both companies will work together to evaluate co-administration of the compounds in a Phase I clinical trial for the treatment of solid cancer tumors. All development costs will be shared jointly, the report said.”
Investors can view all of the Stock Alerts and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
BeaconEquity.com is a Web site wholly owned by BlueWave Advisors, LLC. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BlueWave Advisors LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
